Lenvatinib and pembrolizumab combination in metastatic renal cell carcinoma: experience of the Republic of Bashkortostan

Cover Page

Cite item

Full Text

Abstract

Background. Lenvatinib and pembrolizumab combination showed statistically significant and clinically important improvements for progression-free survival (PFS), overall survival (OS), and objective response rate compared to sunitinib.

Aim. To evaluate the effectiveness and safety of lenvatinib and pembrolizumab combination in patients with metastatic renal cell carcinoma in clinical practice at the Republican Clinical Oncological Dispensary (Ufa).

Materials and methods. The study included 24 patients (20 men and 4 women) with clear cell renal cell carcinoma. Patients with ECOG (Eastern Cooperative Oncology Group) score 0–3, any Karnofsky scale status, and no detection of PD-L1 expression in the tumor were included. Follow-up period was 24 months.

Results. Objective response rate was 68 % which is consistent with the CLEAR trial value of 72 %. Six-month PFS was 82 %, 12-month PFS was 70 %; 6-month OS was 91.2 %, 12-month OS was 83.4 %. Median PFS and OS were not reached. There were no new safety signals for the lenvatinib and pembrolizumab combination. Grade III adverse events were arterial hypertension and hepatotoxicity.

Conclusion. In real clinical practice, lenvatinib and pembrolizumab combination showed results consistent with the data of the basic clinical trial despite short follow-up and expanded inclusion criteria.

About the authors

K. V. Menshikov

Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan;
Bashkir State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: kmenshikov80@bk.ru
ORCID iD: 0000-0003-3734-2779

Konstantin Viktorovich Menshikov 

73/1 Oktyabrya Prospekt, Ufa 450054;
3 Lenina St., Ufa 450008

Russian Federation

D. O. Lipatov

Bashkir State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-3193-9008

3 Lenina St., Ufa 450008

Russian Federation

A. F. Nasretdinov

Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan

ORCID iD: 0000-0001-8340-7962

73/1 Oktyabrya Prospekt, Ufa 450054

Russian Federation

Sh. I. Musin

Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan

ORCID iD: 0000-0003-1185-977X

73/1 Oktyabrya Prospekt, Ufa 450054

Russian Federation

N. I. Sultanbaeva

Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan

ORCID iD: 0000-0001-5926-0446

73/1 Oktyabrya Prospekt, Ufa 450054

Russian Federation

I. A. Menshikova

Bashkir State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-8665-8895

3 Lenina St., Ufa 450008

Russian Federation

A. V. Sultanbaev

Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan;
Bashkir State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0003-0996-5995

73/1 Oktyabrya Prospekt, Ufa 450054;
3 Lenina St., Ufa 450008

Russian Federation

A. A. Izmaylov

Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan

ORCID iD: 0000-0002-8461-9243

73/1 Oktyabrya Prospekt, Ufa 450054

Russian Federation

Sh. N. Galimov

Bashkir State Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-5871-5151

3 Lenina St., Ufa 450008

Russian Federation

A. Sh. Rezyapova

Bashkir State Medical University, Ministry of Health of Russia

3 Lenina St., Ufa 450008

Russian Federation

References

  1. Miller K.D., Goding Sauer A., Ortiz A.P. et al. Cancer statistics for hispanics/latinos, 2018. CA. Cancer J Clin 2018;68(6):425–45. doi: 10.3322/caac.21494
  2. Hsieh J.J., Purdue M.P., Signoretti S. et al. Renal cell carcinoma. Nat Rev Dis Primers 2017;3(1):1–19. doi: 10.1038/nrdp.2017.9
  3. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. doi: 10.3322/caac.21492
  4. Ljungberg B., Campbell S.C., Cho H.Y. et al. The epidemiology of renal cell carcinoma. Eur Urol 2011;60(4):615–21. doi: 10.1016/j.eururo.2011.06.049
  5. Kane C.J., Mallin K., Ritchey J. et al. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 2008;113(1):78–83. doi: 10.1002/cncr.23518
  6. Rossi S.H., Klatte T., Usher-Smith J., Stewart G.D. Epidemiology and screening for renal cancer. World J Urol 2018;36(9):1341–53. doi: 10.1007/s00345-018-2286-7
  7. Capitanio U., Bensalah K., Bex A. et al. Epidemiology of renal cell carcinoma. Eur Urol 2019;75(1):74–84. doi: 10.1016/j.eururo.2018.08.036
  8. Medina-Rico M., Ramos H.L., Lobo M. et al. Epidemiology of renal cancer in developing countries: Review of the literature. Can Urol Assoc J 2018;12(3):E154. doi: 10.5489/cuaj.4464
  9. Vasudev N.S., Wilson M., Stewart G.D. et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. BMJ Open 2020;10(5):e035938. doi: 10.1136/bmjopen-2019-035938
  10. Pavlakis G.M., Sakorafas G.H., Anagnostopoulos G.K. Intestinal metastases from renal cell carcinoma: a rare cause of intestinal obstruction and bleeding. Mt Sinai J Med 2004;71(2):127–30.
  11. Speed J.M., Trinh Q.D., Choueiri T.K., Sun M. Recurrence in localized renal cell carcinoma: a systematic review of contemporary data. Curr Urol Rep 2017;18(2):15. doi: 10.1007/s11934-017-0661-3
  12. Terrone C., Cracco C., Porpiglia F. et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 2006;49:324–31. doi: 10.1016/j.eururo.2005.11.014
  13. Tsui K.H., Shvarts O., Smith R.B. et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000;163(4):1090–5 quiz 1295. doi: 10.1016/s0022-5347(05)67699-9
  14. Wang L.L., Saidian A., Pan E. et al. Adjuvant therapy in renal cell carcinoma: are we ready for prime time? Kidney Cancer 2023;7:1–11.
  15. Mir M.C., Derweesh I., Porpiglia F. et al. Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies. Eur Urol 207;71(4):606–17. doi: 10.1016/j.eururo.2016.08.060
  16. Dhanji S., Wang L., Liu F. et al. Recent advances in the management of localized and locally advanced renal cell carcinoma: a narrative review. Res Rep Urol 2023;15:99–108. doi: 10.2147/RRU.S326987
  17. Yim K., Aron M., Rha K.H. et al. Outcomes of robotassisted partial nephrectomy for clinical T3a renal masses: a multicenter analysis. Eur Urol Focus 2021;7(5):1107–14. doi: 10.1016/j.euf.2020.10.011
  18. Andrade H.S., Zargar H., Akca O. et al. Is robotic partial nephrectomy safe for T3a renal cell carcinoma? Experience of a high-volume center. J Endourol 2017;31(2):153–7. doi: 10.1089/end.2016.0622
  19. Campbell S.C., Clark P.E., Chang S.S. et al. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part I. J Urol 2021;206(2):199–208. doi: 10.1097/JU.0000000000001911
  20. Pierorazio P.M., Johnson M.H., Patel H.D. et al. AHRQ comparative effectiveness reviews. In Management of renal masses and localized renal cancer. Rockville (MD): Agency for Healthcare Research and Quality (US) 2016.
  21. Pierorazio P.M., Johnson M.H., Patel H.D. et al. Management of renal masses and localized renal cancer: systematic review and meta-analysis. J Urol 2016;196(4):989–99. doi: 10.1016/j.juro.2016.04.081
  22. Bukavina L., Bensalah K., Bray F. et al. Epidemiology of renal cell carcinoma: 2022 update. Eur Urol 2022;82(5):529–42. doi: 10.1016/j.eururo.2022.08.019
  23. Barata P.C., Rini B.I. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin 2017;67(6):507–24. doi: 10.3322/caac.21411
  24. Attalla K., Weng S., Voss M.H., Hakimi A.A. Epidemiology, risk assessment, and biomarkers for patients with advanced renal cell carcinoma. Urol Clin 2020;47(3):293–303. doi: 10.1016/j.ucl.2020.04.002
  25. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2017. CA A Cancer J. Clin 2017;67(1):7–30. doi: 10.3322/caac.21387
  26. He Y., Luo Y., Huang L. et al. New frontiers against sorafenib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers. Pharmacol Res 2021;170:105732. doi: 10.1016/j.phrs.2021.105732
  27. Gong C., Ji Q., Wu M. et al. Ferroptosis in tumor immunity and therapy. J Cell Mol Med 2022;26(22):5565–79. doi: 10.1111/jcmm.17529
  28. Meng Y., Sun H., Li Y. et al. Targeting ferroptosis by ubiquitin system enzymes: a potential therapeutic strategy in cancer. Int J Biol Sci 2022;18(14):5475–88. doi: 10.7150/ijbs.73790
  29. Motzer R., Alekseev B., Rha S.Y. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384:1289–300. doi: 10.1056/NEJMoa2035716
  30. Dudani S., de Velasco G., Wells J.C. et al. Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival. JAMA Netw Open 2021;4:e2021869. doi: 10.1001/jamanetworkopen.2020.21869
  31. Wei H., Miao J., Cui J. et al. The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database. Sci Rep 2021;11:17822. doi: 10.1038/s41598-021-97365-6
  32. Hahn A.W., Lebenthal J., Genovese G. et al. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 2022;33:100640. doi: 10.1016/j.ctarc.2022.100640
  33. Grünwald V., Powles T., Eto M. et al. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Front Oncol 2023 16;13:1223282. doi: 10.3389/fonc.2023.1223282 (Erratum in: Front Oncol 2024;13:1343027. doi: 10.3389/fonc.2023.1343027)

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.